Our radiopharmaceutical CDMO services span the entire spectrum of the targeted radiotherapy journey and are tailored to our customers’ needs.
Whether you’re a biotech startup with a new drug molecule seeking research and development support for drug approval, a pharmaceutical company with an FDA-approved drug seeking additional manufacturing space, or anywhere in between, we’ve got you covered.
The path to bringing radiotherapies to market is risky, but it doesn’t have to be. With the right expertise and resources, you can safeguard your investments and accelerate time to market.
Our expert team provides end-to-end CDMO support tailored to your unique goals—from assisting with clinical trials, offering regulatory guidance, and advising on radiopharmaceutical quality assurance to safe and rapid manufacturing and delivery via our facilities and interconnected resource network.
With hundreds of new theranostics in clinical trials, radiopharmaceutical manufacturing capacity has been a significant constraint for currently FDA-approved radioligand therapies.
By leveraging our unique manufacturing footprint as a “plan B,” you can create redundancy and mitigate risks associated with supply chain disruptions, raw material shortages, or unexpected demand surges to ensure continuity without compromising quality.
Our team of seasoned industry leaders brings 150+ collective years of experience in manufacturing and 250+ collective years of experience in radiopharmaceutical supply chain to the table.
Building development and manufacturing facilities in proximity to prominent destination medical centers and key distribution hubs allows us to expedite drug production and ensure your life-saving treatments reach patients precisely when they need them.
We’ve woven a tight web across the entire supply chain with our customers in mind—from hospitals and universities to radioisotope suppliers and regulatory agencies. This interconnected network gives us unparalleled insights and resources to navigate the complex world of radiotherapies.
To avoid potential conflicts of interest, risks to your intellectual property, and issues with resource allocation, our sole focus is your drug—we don’t develop our own.
